People using ADHD medicines for a long time may have higher risk of cardiovascular diseases

In­vivyd on Mon­day re­port­ed pos­i­tive ear­ly Phase III da­ta for its mon­o­clon­al an­ti­body de­signed to pre­vent symp­to­matic Covid-19 among im­muno­com­pro­mised in­di­vid­u­als, trig­ger­ing the biotech’s stock

UniQure shared up­dat­ed da­ta from a Phase I/II study that showed a clin­i­cal ben­e­fit in a small group of pa­tients with Hunt­ing­ton’s dis­ease who re­ceived